More than $486 Billion in New U.S. Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $486 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. Our continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,471%
increase in announced U.S. facility investments versus 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Oct 20, 2025
Merck
$70 billion
Unspecified location
Investment in U.S. capital projects, research and development to drive long-term growth and fortify America’s position as a global leader in drug innovation.
Amount includes previously announced projects in Rahway, NJ, Wilmington, DE, and Elkton, VA, which represent an estimated $7.5 billion commitment. The company also disclosed $3 billion in planned biologics and small molecule manufacturing sites and capabilities in the U.S., projected to create 800 additional jobs.
Oct 20, 2025
Merck
$3 billion
Elkton–VA
Broke ground on a project to enhance an existing site with a 400,000-square-foot Center of Excellence for pharmaceutical manufacturing. The facility will support small molecule manufacturing and testing and will potentially create more than 500 full-time roles as well as 8,000 construction jobs.
Part of a $70 billion U.S. investment plan.
Oct 10, 2025
Ypsomed
$248 million
Holly Springs-NC
A 15,000-square-meter factory that will be the Switzerland-based company’s first manufacturing facility in the United States. The facility will supply products solely for the U.S. market and is expected to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
Oct 9, 2025
AstraZeneca
$4.5 billion
Albemarle-VA
A new manufacturing facility that is scheduled to increase output of various medicines, including cancer treatments, once operational within the next five to six years. Will create 3,600 direct and indirect jobs, including 3,000 tied to the project's construction phase.
Part of a larger, previously announced $50 billion investment.
Sep 23, 2025
Eli Lilly
$6.5 billion
Houston-TX
New next-generation API manufacturing facility that will focus on small molecule medicines across several therapeutic areas, including cardiometabolic health, immunology, neuroscience and oncology. Scheduled to be operational within five years, the facility will create 615 permanent high-wage jobs plus 4,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
Sep 17, 2025
GSK
$30 billion
PA, NC, MD, MT
A five-year commitment to upgrade research and development and supply chain infrastructure. Includes a $1.2 billion investment in advanced U.S. manufacturing and digital capabilities, including a new biologics flex factory in Upper Merion, Pa., to produce next-generation respiratory and cancer medicines.
The investment will also bring AI and advanced digital technologies to GSK’s five existing sites in Pennsylvania, North Carolina, Maryland, and Montana, along with expanded drug substance, device, and auto-injector capabilities.
Sep 16, 2025
Eli Lilly
$5 billion
Goochland County-VA
New $5 billion manufacturing facility is part of a larger, previously announced $27 billion company investment. Three other new U.S. sites will be finalized in 2025. According to Lilly, the Richmond-area development will be the “first dedicated, fully integrated API and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio. About 1,800 construction jobs and more than 650 new high-paying jobs, including engineers, scientists and lab technicians, will be brought to region.
Sep 3, 2025
Gilead
Unspecified
Foster City-CA
A new facility that will enhance technical development and manufacturing through advanced automation, robotics, and digital monitoring. The project also expands the company’s focus on biologics.
Part of a $4 billion commitment in 2025 to U.S. capital projects.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page